Scientists have uncovered how a key type of immune cell adapts its behavior depending on the type of infection, paving the way for better vaccines and advancing research into immune-related diseases.

The first patient has been dosed in the phase 3 TERZO trial of Copiktra for relapsed or refractory nodal T-follicular helper cell lymphoma. The first patient has been dosed in the phase 3 TERZO study ...

After spending years tracing the origin and migration pattern of an unusual type of immune cell in mice, researchers headed by a team at The Ohio State University College of Medicine have shown how ...

Understanding the interplay between T cells and B cells is pivotal to delineating both protective immunity and the pathogenesis of autoimmune diseases. Central to this dynamic are specialised CD4⁺ T ...

Arvinas, Inc. announced promising preclinical results for ARV-393, an investigational PROTAC BCL6 degrader, showing significant single-agent activity against nodal T-follicular helper cell lymphoma ...

A researcher at the Hackensack Meridian Center for Discovery and Innovation (CDI) and physician-scientist colleagues from Hackensack Meridian Health have shown how a critical pathway is fundamental to ...

SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced ...

A team of researchers at UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and potentially reverse, immune checkpoint inhibitor (ICI)–induced type I ...

Relapsed/refractory peripheral and cutaneous T-cell lymphomas (R/R PTCL and CTCL) are aggressive blood cancers that often resist standard therapy. Patients with these lymphomas may require stem cell ...

Arvinas, Inc. announced that it will present new preclinical data on its investigational oral PROTAC BCL6 degrader, ARV-393, at the upcoming European Hematology Association (EHA) meeting in Milan from ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment, according to ...